CLEC2D and glioblastoma: Several studies from us and others on CD161 showed that CD161 is highly expressed in GBM (23–25), which verified that restraining the CLEC2D-CD161 pathway may strengthen T cell-mediated immunity against GBM to a certain extent (12).